Historically, kidney cancer was approached in a siloed single-speciality way, with urological
surgeons managing the localised stages of the disease and medical oncologists caring for …

Aim To update the recommendations for the management of kidney cancers. Methods A
systematic review of the literature was conducted from 2015 to 2022. The most relevant …

Background Predictive tools can be useful for adapting surveillance or including patients in
adjuvant trials after surgical resection of nonmetastatic renal cell carcinoma (RCC). Current …

Renal cell carcinoma (RCC) is most often diagnosed at a localized stage, where surgery is
the standard of care. Existing prognostic scores provide moderate predictive performance …

Objectives To synthesise available data regarding the disease‐free survival (DFS) benefit of
adjuvant immune checkpoint inhibitors (ICIs) for patients with renal cell carcinoma (RCC) …

Background To develop a novel nomogram for predicting 2-year and 5-year disease-free
survival (DFS) and overall survival (OS) in patients with cT1-clear cell renal cell carcinoma …

Simple Summary To date, guideline-recommended prognostic models predicting cancer-
control outcomes in chromophobe kidney cancer patients have never been validated in a …

Background: Accurate prognostication of oncological outcomes is crucial for the optimal
management of patients with renal cell carcinoma (RCC) after surgery. Previous prediction …

Background Retrospective comparative studies suggest a survival benefit after complete
local treatment of recurrence (LTR) in renal cell carcinoma (RCC), which may be largely due …

Background: Current prognostic models have limited predictive abilities for the growing
number of localized (stage I–III) ccRCCs. It is, therefore, crucial to explore novel …